Maryland’s Prescription Drug Affordability Board approved upper payment limits for two prescription drugs, with implementation planned for Jan. 1. Industry advocates argue the mechanism is unlikely to lower what patients pay out of pocket because the caps apply to what state and local purchasers and insurers cover—not the pharmacy counter price. The debate highlights how PDAB-style rate-setting differs from direct patient affordability levers. Critics also warn that price controls can affect access and investment incentives. In Maryland’s case, the board decision is being positioned as a standout effort as other states reassess or roll back PDAB plans, although legal challenges in comparable jurisdictions remain in play.
Get the Daily Brief